An interventional study of altitude exposure in Chronic Obstructive Pulmonary Disease (COPD), sponsored by University of Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-05-19.
Sponsored by University of Zurich · Not applicable and Interventional
The purpose of this study is to investigate the effect of a stay at moderate altitude on exercise performance of patients with chronic obstructive lung disease.
Patients with moderate to severe COPD living below 800 m, will be recruited to participate in a randomized cross-over field trial evaluating the hypothesis that exercise capacity during a 4 day sojourn at moderate altitude is reduced in comparison to low altitude. Outcomes will be assessed during 2 days in Zurich (490 m, low altitude baseline), 2 days at Davos Clavadel (1650 m), and 2 days at Davos Jakobshorn (2590 m). The main outcome is the 6 minute walk distance.
4,252 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.
This study's planned enrollment of 50 is below the median of 70 across 3,008 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →University of Zurich is the lead sponsor of 1,048 studies on the registry; 131 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Altitude exposure sequence A, 490-1630-2590m
Other: altitude exposure
Altitude exposure sequence B, 490-2590-1630 m
Other: altitude exposure
Altitude exposure sequence C, 1630-2590-490 m
Other: altitude exposure
Altitude exposure sequence D, 2590-1630-490 m
Other: altitude exposure
stay at different altitudes: 490, 1630, 2590 m
Change in exercise performance from baseline measured at 490 m
6 min walk distance
Time frame: Change in 6 min walk distance from 490 m baseline during 2 days at 2590 m
Change in exercise performance from baseline measured at 490 m
6 min walk distance
Time frame: Change in 6 min walk distance from 490 m baseline during 2 days at 1650 m
Change in pulmonary function from baseline measured at 490 m
lung volumes by spirometry
Time frame: Change in pulmonary function from 490 m baseline during 2 days at 2590 m
Change in pulmonary function from baseline measured at 490 m
lung volumes by spirometry
Time frame: Change in pulmonary function from 490 m baseline during 2 days at 1650 m
Change in arterial blood gases from baseline measured at 490 m
Arterial blood gas analysis
Time frame: Change in arterial blood gases from 490 m baseline during 2 days at 2590 m
Change in arterial blood gases from baseline measured at 490 m
Arterial blood gas analysis
Time frame: Change in arterial blood gases from 490 m baseline during 2 days at 1650 m
Change in perceived exertion from baseline measured at 490 m
Borg CR10 scale at end of 6 min walk
Time frame: Change in perceived exertion from 490 m baseline during 2 days at 2590 m
Change in perceived exertion from baseline measured at 490 m
Borg CR10 scale at end of 6 min walk
Time frame: Change in perceived exertion from 490 m baseline during 2 days at 1650 m
The record gives a start of May 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →